EMEA accepts IV vernakalant MAA

EMEA accepted for review an MAA from Merck & Co. Inc. (NYSE:MRK) for IV vernakalant to treat acute atrial fibrillation. Merck has rights to the IV formulation of the mixed ion channel antagonist outside the U.S., Canada and Mexico from Cardiome Pharma Corp. (TSX:COM; NASDAQ:CRME). ...